SG11201909726YA - METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF - Google Patents
METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOFInfo
- Publication number
- SG11201909726YA SG11201909726YA SG11201909726YA SG11201909726YA SG 11201909726Y A SG11201909726Y A SG 11201909726YA SG 11201909726Y A SG11201909726Y A SG 11201909726YA SG 11201909726Y A SG11201909726Y A SG 11201909726YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- acetaminophen
- composition
- nsaids
- optionally
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title abstract 10
- 239000000203 mixture Substances 0.000 title abstract 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title abstract 5
- 229960005489 paracetamol Drugs 0.000 title abstract 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 229910052760 oxygen Inorganic materials 0.000 title abstract 4
- 239000001301 oxygen Substances 0.000 title abstract 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008215 water for injection Substances 0.000 abstract 2
- 238000013329 compounding Methods 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT o mum I E l0 00111101101110 011 (10) International Publication Number WO 2018/193099 Al (51) International Patent Classification: A61K 9/08 (2006.01) A61K 31/192 (2006.01) A61K 31/167 (2006.01) (21) International Application Number: Published: — with international search report (Art. 21(3)) PCT/EP2018/060205 (22) International Filing Date: 20 April 2018 (20.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2017/059440 20 April 2017 (20.04.2017) EP (71) Applicant: HYLORIS DEVELOPMENTS SA [BE/BE]; Avenue Hippocrate 5, 4000 Liege (BE). (72) Inventor: JACOBSEN, Thomas; Avenue Hippocrate 5, 4000 Liege (BE). (74) Agent: BRANTSANDPATENTS BVBA; Pauline Van Pottelsberghelaan 24, 9051 Ghent (BE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) ON (54) Title: METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ON ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF O M (57) : The present invention provides a method for preparing an intravenously administrable aqueous composition comprising CN acetaminophen, and optionally one or more non-steroidal anti-inflammatory drugs (NSAIDs), whereby the dissolved oxygen of the 1-1 composition in a closed container is maximally 1.0 ppm, said method comprises rinsingat least once a compounding vessel with water of a temperature of at least 80°C, thereby heating the vessel and creating an oxygen low environment in said vessel; and in said rinsed 1-1 c;;;;) vessel dissolving acetaminophen in water for injection, said water for injection is at a temperature of at least 80°C, whereby optionally N one or more NSAIDS are added prior or after dissolving of acetaminophen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2017/059440 WO2018192664A1 (en) | 2017-04-20 | 2017-04-20 | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
| PCT/EP2018/060205 WO2018193099A1 (en) | 2017-04-20 | 2018-04-20 | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909726YA true SG11201909726YA (en) | 2019-11-28 |
Family
ID=58645031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909726Y SG11201909726YA (en) | 2017-04-20 | 2018-04-20 | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11413241B2 (en) |
| EP (1) | EP3612157A1 (en) |
| JP (1) | JP6944590B2 (en) |
| KR (2) | KR102625301B1 (en) |
| CN (1) | CN110719773A (en) |
| AR (1) | AR111484A1 (en) |
| AU (1) | AU2018255376B2 (en) |
| CA (1) | CA3060325A1 (en) |
| CL (1) | CL2019002985A1 (en) |
| CO (1) | CO2019011569A2 (en) |
| EC (1) | ECSP19075614A (en) |
| IL (1) | IL270035B2 (en) |
| MX (1) | MX2019012508A (en) |
| PE (1) | PE20191793A1 (en) |
| PH (1) | PH12019502385A1 (en) |
| RU (1) | RU2019137019A (en) |
| SA (1) | SA519410340B1 (en) |
| SG (1) | SG11201909726YA (en) |
| TW (1) | TW201841632A (en) |
| WO (2) | WO2018192664A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016008546A1 (en) | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
| UY38573A (en) * | 2019-03-05 | 2020-09-30 | Grifols Worldwide Operations Ltd | PROCEDURE FOR THE PREPARATION OF CONTAINERS OF HEMODERIVATED PRODUCTS |
| CN115040475A (en) * | 2022-06-23 | 2022-09-13 | 杭州浙中医药科技有限公司 | N-acetylcysteine oral solution |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751875B1 (en) | 1996-08-05 | 1998-12-24 | Scr Newpharm | NOVEL STABLE LIQUID FORMULATIONS BASED ON PARACETAMOL AND THEIR METHOD OF PREPARATION |
| FR2809619B1 (en) * | 2000-06-06 | 2004-09-24 | Pharmatop | NOVEL AQUEOUS FORMULATIONS OF OXIDATION-SENSITIVE ACTIVE INGREDIENTS AND PROCESS FOR OBTAINING THEM |
| US20060100578A1 (en) | 2004-09-13 | 2006-05-11 | Tandem Medical, Inc. | Medication delivery apparatus and methods for intravenous infusions |
| KR20110065417A (en) | 2008-01-03 | 2011-06-15 | 욱크하르트 리미티드 | Oral pharmaceutical suspension comprising paracetamol and ibuprofen |
| KR20110112279A (en) | 2008-10-14 | 2011-10-12 | 에이에프티 파마슈티칼스 리미티드 | A medicinal product and treatment |
| EP2243477A1 (en) | 2009-04-22 | 2010-10-27 | Fresenius Kabi Deutschland GmbH | Paracetamol for parenteral application |
| US8404748B2 (en) | 2009-08-13 | 2013-03-26 | Neogen N.V. | Storage-stable formulation of paracetamol in aqueous solution |
| ES2403121T3 (en) | 2010-05-19 | 2013-05-14 | Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | Formulation of injectable paracetamol, stable, ready to use |
| HUE045442T2 (en) | 2010-11-04 | 2019-12-30 | Aft Pharmaceuticals Ltd | A combination composition |
| US9205037B2 (en) | 2011-07-20 | 2015-12-08 | Church & Dwight Co., Inc. | Single phase depilatory composition |
| ES2414557B1 (en) * | 2012-01-16 | 2014-06-10 | Novocat Farma, S.A. | Aqueous composition of paracetamol for injection |
| BE1020614A5 (en) | 2012-01-27 | 2014-01-07 | Hubert De Backer Nv | SYRINGE. |
| US9072661B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| CA2867477C (en) | 2012-03-16 | 2017-09-26 | Cumberland Pharmaceuticals, Inc. | Injectable ibuprofen formulation |
| WO2016008546A1 (en) | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
-
2017
- 2017-04-20 WO PCT/EP2017/059440 patent/WO2018192664A1/en active Application Filing
-
2018
- 2018-04-18 TW TW107113225A patent/TW201841632A/en unknown
- 2018-04-20 WO PCT/EP2018/060205 patent/WO2018193099A1/en active Search and Examination
- 2018-04-20 PE PE2019002070A patent/PE20191793A1/en unknown
- 2018-04-20 JP JP2020508076A patent/JP6944590B2/en active Active
- 2018-04-20 US US16/605,711 patent/US11413241B2/en active Active
- 2018-04-20 RU RU2019137019A patent/RU2019137019A/en unknown
- 2018-04-20 MX MX2019012508A patent/MX2019012508A/en unknown
- 2018-04-20 AR ARP180101010A patent/AR111484A1/en unknown
- 2018-04-20 CN CN201880035790.3A patent/CN110719773A/en active Pending
- 2018-04-20 AU AU2018255376A patent/AU2018255376B2/en active Active
- 2018-04-20 CA CA3060325A patent/CA3060325A1/en active Pending
- 2018-04-20 EP EP18718164.9A patent/EP3612157A1/en active Pending
- 2018-04-20 KR KR1020197032849A patent/KR102625301B1/en active IP Right Grant
- 2018-04-20 KR KR1020237039452A patent/KR20230160413A/en not_active Application Discontinuation
- 2018-04-20 SG SG11201909726Y patent/SG11201909726YA/en unknown
-
2019
- 2019-10-17 IL IL270035A patent/IL270035B2/en unknown
- 2019-10-18 CL CL2019002985A patent/CL2019002985A1/en unknown
- 2019-10-18 CO CONC2019/0011569A patent/CO2019011569A2/en unknown
- 2019-10-20 SA SA519410340A patent/SA519410340B1/en unknown
- 2019-10-21 EC ECSENADI201975614A patent/ECSP19075614A/en unknown
- 2019-10-21 PH PH12019502385A patent/PH12019502385A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201841632A (en) | 2018-12-01 |
| CA3060325A1 (en) | 2018-10-25 |
| IL270035B2 (en) | 2023-05-01 |
| PE20191793A1 (en) | 2019-12-24 |
| CL2019002985A1 (en) | 2020-01-31 |
| WO2018193099A1 (en) | 2018-10-25 |
| CO2019011569A2 (en) | 2021-03-08 |
| JP6944590B2 (en) | 2021-10-06 |
| ECSP19075614A (en) | 2019-11-30 |
| JP2020522564A (en) | 2020-07-30 |
| IL270035B1 (en) | 2023-01-01 |
| RU2019137019A3 (en) | 2021-07-05 |
| MX2019012508A (en) | 2020-02-05 |
| AU2018255376A1 (en) | 2019-11-07 |
| AU2018255376B2 (en) | 2023-07-06 |
| KR20230160413A (en) | 2023-11-23 |
| KR102625301B1 (en) | 2024-01-15 |
| US20210338578A1 (en) | 2021-11-04 |
| KR20190137859A (en) | 2019-12-11 |
| SA519410340B1 (en) | 2022-03-13 |
| WO2018192664A1 (en) | 2018-10-25 |
| EP3612157A1 (en) | 2020-02-26 |
| US11413241B2 (en) | 2022-08-16 |
| CN110719773A (en) | 2020-01-21 |
| AR111484A1 (en) | 2019-07-17 |
| RU2019137019A (en) | 2021-05-20 |
| IL270035A (en) | 2019-12-31 |
| PH12019502385A1 (en) | 2020-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201909656YA (en) | Intracellular kinase associated with resistance against anti-tumour immune responses, and uses thereof | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201902531QA (en) | Liquid pharmaceutical composition | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations | |
| SG11201909726YA (en) | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201803643TA (en) | Virulence attenuated bacteria for treatment of malignant solid tumors | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound |